Trevi Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Trevi Therapeutics

08/05/2025 22:02

Trevi Therapeutics Inc TRVI.OQ reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -11 cents.  The mean expectation of nine analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -15 cents to -10 cents per share.

Reported revenue was zero​; analysts expected zero.

Trevi Therapeutics Inc's reported EPS for the quarter was a loss of 9 cents​.

The company reported a quarterly loss of $10.34 million.

Trevi Therapeutics Inc shares had risen by 5.9% this quarter and gained 61.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 2.3% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Trevi Therapeutics Inc is $20.00

This summary was machine generated from LSEG data May 8 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.12
-0.09
Beat
Dec. 31 2024
-0.12
-0.11
Beat
Sep. 30 2024
-0.12
-0.13
Missed
Jun. 30 2024
-0.11
-0.12
Missed